New research describes a molecular tool that shows great promise as a therapeutic for human acute myeloid leukemia, a notoriously treatment-resistant blood cancer. The study describes exciting preclinical studies in which a new therapeutic approach selectively attacks human cancer cells grown in the lab and in animal models of leukemia.